Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

Biomarker analyses provided proof of a mechanism during combination therapy.Yap and his colleagues observed increased CD8+ T cell infiltration and activation in tumors, reduced the regulatory T ...

A nationwide cohort study in Taiwan found a higher risk of psoriasis in cancer patients treated with immune checkpoint inhibitors compared to other therapies. The study analyzed data from 3,188 ...

Three years after enrolling its first patients, a consortium of researchers examining the growing issue of immune-related adverse events due to immune checkpoint inhibitor cancer therapy released a ...

This Research Topic is Volume II of a series. The previous volume, which has attracted over 21k views can be found here: New Tumor Immune Checkpoints and ...

Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time This retrospective cohort study included ...

Oncodermatology is evolving with nonsurgical approaches and immune checkpoint inhibitors, improving outcomes in aggressive ...

The FDA has granted fast track designation to the investigational oncolytic virus immunotherapy pelareorep (Reolysin) in combination with bevacizumab (Avastin) and FOLFIRI (leucovorin, fluorouracil, ...

Outcomes of patients treated with dabrafenib and trametinib who developed pyrexia syndrome and severe/complicated pyrexia syndrome. Comparison between extended and standard infusion in patients with ...

Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...

A key molecular mechanism drives the growth of liver cell cancer while simultaneously suppressing the body's immune response ...

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...